Bio-Convert's Revolutionary QR-02 Treatment
Bio-Convert ApS, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD), has pioneered a groundbreaking oral therapeutic called QR-02. This innovative treatment aims to combat oral leukoplakia, particularly in cases of moderate to severe dysplasia—a condition that could potentially escalate to cancer and affect millions globally.
The Urgency of Addressing Oral Leukoplakia
Oral leukoplakia manifests through white patches within the oral cavity, and its association with dysplasia raises concerns about disease progression. Alarmingly, a significant percentage of individuals—ranging from 10% to 30%—may face the grim possibility of developing oral cancer, which shows a troubling survival rate of less than 50% over five years.
In the United States and Europe alone, there are approximately 15.5 million individuals diagnosed with oral leukoplakia. This statistic underscores the pressing need for effective treatment solutions that can prevent the advancement of this condition. Notably, the majority of these lesions—around 80%—occur within the oral cavity, highlighting the importance of a long-lasting therapeutic approach.
Innovative Features of QR-02
The QR-02 treatment stands out due to its unique mucoadhesive formulation, which allows it to adhere to the oral tissues for a remarkable duration of 12 to 24 hours. This shift away from traditional treatment options, which typically last only 15 to 20 minutes due to saliva washout, marks a significant improvement in the effectiveness of oral therapies.
Imiquimod, the active ingredient in QR-02, is widely recognized for its FDA-approved use in treating various superficial skin conditions such as Actinic Keratosis and External Genital Warts. However, Bio-Convert's distinct formulation of imiquimod for oral application provides fresh hope for those suffering from oral leukoplakia. Additionally, this treatment may offer benefits for other related oral health conditions that can arise in these patients.
Transformative Impact on Patient Health
Bio-Convert aims for QR-02 to significantly reduce dysplasia in patients with oral leukoplakia, potentially providing a curative effect that would represent a remarkable advancement in oral health care. By addressing oral leukoplakia during its earlier stages, QR-02 holds the promise of improving overall health outcomes for patients facing this challenging condition.
Path to Clinical Validation
Currently, Bio-Convert is steering QR-02 through the necessary stages of clinical trials to validate its effectiveness. The goal is to bring this groundbreaking treatment to those in need, significantly enhancing the landscape of oral medicine. CEO and Founder Allan Wehnert expressed enthusiasm about the potential impact of QR-02, stating, "We are incredibly proud of this invention and the impact it will have on patients. Our hope is that patients may return to a normal life and, potentially, be cured of their illness."
Contact and Further Information
For more details, interested parties are encouraged to reach out to:
Mr. Henrik Rouf
Chief Executive Officer
Phone: +1 310 666 0750
Email: hr@nordicuspartners.com
Investor Relations:
Jonathan Paterson
Harbor Access Investor Relations
Email: Jonathan.Paterson@Harbor-Access.com
Tel: +1 475 477 9401
Frequently Asked Questions
What is QR-02?
QR-02 is an innovative topical treatment developed by Bio-Convert to combat oral leukoplakia associated with moderate to severe dysplasia.
How does QR-02 work?
QR-02 utilizes a mucoadhesive formulation that allows prolonged adherence in the oral cavity, enhancing treatment effectiveness compared to conventional therapies.
What are the potential benefits of QR-02?
The treatment is designed to significantly reduce dysplasia levels, offering hope for a curative approach to oral leukoplakia and improving patient health outcomes.
Who developed QR-02?
QR-02 was developed by Bio-Convert ApS, a subsidiary of Nordicus Partners Corporation, which focuses on advancing life sciences innovations.
How can patients learn more about QR-02?
Patients and interested parties can contact Bio-Convert's CEO or Investor Relations for further information regarding QR-02 and its clinical trials.
